Ketamine and Motivational Enhancement Therapy for the Treatment of Tobacco Use Disorder
NCT05796791
Completed
The purpose of the study is to examine whether an investigational medication called ketamine is able to improve treatment outcomes for tobacco use disorder when delivered in conjunction with brief motivational enhancement therapy. Participants will receive ketamine assisted motivational enhancement therapy weekly for three weeks and there will be 2 follow up visits. All visits will also consist of questionnaires and saliva samples will be taken. The overall participation will last approximately... Read More
Gender:
ALL
Ages:
Between 21 years and 65 years
Trial Updated:
07/17/2025
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Tobacco Use, Smoking Cessation, Nicotine Dependence
Register for Updates
Prehospital Analgesia INtervention Trial (PAIN)
NCT05437575
Recruiting
The Prehospital Analgesia INtervention trial (PAIN) is a proposed 4 year (3-year enrollment) multicenter, prehospital, randomized, double-blind, clinical trial that will enroll approximately 994 patients at select LITES Network sites. The objective is to perform a prospective, interventional, randomized trial among prehospital trauma patients with compensated shock (SI≥0.9) and an indication for pain management, comparing patient centered outcomes following prehospital administration of ketamine... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/15/2025
Locations: University of California, San Diego, San Diego, California +9 locations
Conditions: Traumatic Injury
Register for Updates
Ketamine-Assisted Psychotherapy (KAP) Compared to Ketamine Alone for the Treatment of Depression
NCT06559826
Recruiting
The proposed study is a single-site, randomized, controlled clinical trial (RCT) comparing ketamine-assisted psychotherapy (KAP) to a standard evidence-based regimen of ketamine administered in a medical model without psychotherapy (KET). Eligible study participants will be adults with major depressive disorder (MDD). Adults with MDD will be randomized to KAP or KET in a 1:1 allocation. Each treatment group will receive KAP or KET over a period of four weeks. Measurement of depression severity,... Read More
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
07/10/2025
Locations: Icahn School of Medicine at Mount Sinai, New York, New York
Conditions: Major Depressive Disorder
Register for Updates
Ketamine HCl Prolonged Release Oral Tablets for CRPS
NCT06419985
Not Yet Recruiting
The purpose of this study is to evaluate the efficacy of Ketamine HCl Prolonged Release (PR) tablets in participants with pain due to complex regional pain syndrome (CRPS). Additionally, this trial will explore the feasibility of the trial design through dosing compliance, clinical instruments for safety and quality of life measurements, and pharmacokinetic profile.
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
07/10/2025
Locations: Pain Center, Keck Medical Center of University of Southern California, Los Angeles, California
Conditions: Complex Regional Pain Syndromes
Register for Updates
Ketamine for Sedation in Severe Traumatic Brain Injury
NCT06429657
Suspended
This protocol is for an open-label randomized trial evaluating the safety of using ketamine in combination with propofol for sedation versus the standard of care analgosedation in patients admitted to the intensive care unit with severe traumatic brain injury.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/10/2025
Locations: Brooke Army Medical Center, Fort Sam Houston, Texas
Conditions: Severe Traumatic Brain Injury, Intracranial Hypertension, Intracranial Hemorrhage, Hypertensive
Register for Updates
Imaging Depression in Parkinson's Disease
NCT06402955
Recruiting
The goal of this observational study is to identify targetable neural substrates of depression in Parkinson's Disease for the first time in people with Parkinson's between the ages of 40 and 80, who are experiencing symptoms of depression.
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
07/09/2025
Locations: Yale University, New Haven, Connecticut
Conditions: Parkinson's Disease, Major Depressive Disorder
Register for Updates
Psilocybin-Assisted vs Ketamine-Assisted Psychotherapy for Alcohol Use Disorder
NCT05421065
Active Not Recruiting
This pilot study will collect preliminary data that measures the effects of psilocybin-assisted psychotherapy vs ketamine-assisted psychotherapy on patients struggling with alcohol use.
Gender:
MALE
Ages:
Between 25 years and 65 years
Trial Updated:
07/09/2025
Locations: University of Iowa, Iowa CIty, Iowa
Conditions: Alcohol Use Disorder
Register for Updates
Feasibility Study of Oral Ketamine Versus Placebo for the Treatment of Anxiety in Patients With Pancreatic Cancer
NCT05086250
Recruiting
This is a prospective, single center, double blind, randomized, crossover feasibility study of oral ketamine versus placebo for the treatment of anxiety in patients with pancreatic cancer currently receiving or within 12 weeks of receiving cancer targeted therapy. The primary objective is to determine the feasibility of enrolling subjects and treatment adherence. The secondary objectives are to describe the safety and tolerability. Exploratory objectives are to assess the effect of ketamine/plac... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/09/2025
Locations: Cedars-Sinai Medical Center, Los Angeles, California
Conditions: Anxiety, Pancreatic Cancer
Register for Updates
Psilocybin vs Ketamine for Alcohol Use Disorder
NCT06405607
Recruiting
This study will collect data that measures the effects of a psychedelic intervention on patients struggling with alcohol use disorder (AUD). The study design will be a double blind, randomized, active-comparator trial with two study arms. Subjects randomized to Arm 1 (n=40) will receive individual psychotherapy sessions plus a 30 mg dose of psilocybin. Arm 2 subjects (n=40) will receive individual psychotherapy sessions and a 0.75 mg/kg dose of ketamine.
Gender:
ALL
Ages:
Between 21 years and 65 years
Trial Updated:
07/09/2025
Locations: University of Iowa Health Care, Iowa City, Iowa
Conditions: Alcohol Use Disorder, Alcohol Dependence, Alcohol Abuse
Register for Updates
Glutamatergic Mechanisms of Psychosis and Target Engagement (SA1)
NCT04589208
Suspended
50 healthy volunteers (HV) will participate in 2 identical ketamine-induced pharmacoBOLD (phBOLD) sessions at least 7 days apart. On both days, clinical assessments will be performed following removal of the subject from the scanner. HV will be discharged home after clearance by the study physician. This study will assign ketamine doses in successive 10 subject cohorts. The ketamine dose for the 1st cohort will start at 0.08 mg/kg. For subsequent cohorts, the bolus will be successively reduced... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
07/08/2025
Locations: New York State Psychiatric, New York, New York
Conditions: Healthy
Register for Updates
Feasibility and Safety of Ketamine for Suicidal Patients in the Emergency Department
NCT06085937
Recruiting
There is currently no readily available pharmacologic intervention for suicidal ideation, a true psychiatric emergency, in the Emergency Department (ED). Investigators aim to trial low-dose, intravenous ketamine, a drug with well-established use in treatment-resistant depression, for patients who present to the ED with suicidal ideation.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/07/2025
Locations: University of Kansas Strawberry Hill Campus, Kansas City, Kansas +1 locations
Conditions: Suicide, Suicidal Ideation, Depression
Register for Updates
The Effects of Sedatives on Tobacco Use Disorder Version 2
NCT05505630
Active Not Recruiting
Double-blind, placebo-controlled, randomized mechanistic clinical trial to test an intravenous dose of either ketamine, midazolam, dexmedetomidine, or a placebo (saline) on cigarette smoking behavior, craving, and neural effects.
Gender:
ALL
Ages:
Between 21 years and 55 years
Trial Updated:
07/03/2025
Locations: Wake Forest University Health Sciences, Winston-Salem, North Carolina
Conditions: Tobacco Smoking
Register for Updates